Stay updated with breaking news from Affimed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HEIDELBERG, Germany, May 22, 2023 -- Affimed N.V. , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2023... | May 22, 2023
StockNews.com began coverage on shares of Affimed (NASDAQ:AFMD – Get Rating) in a research note released on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock. Other analysts have also issued reports about the company. Wells Fargo & Company reiterated an overweight rating and set a $7.00 price target on shares of […]
Research analysts at StockNews.com started coverage on shares of Affimed (NASDAQ:AFMD – Get Rating) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Several other analysts have also recently commented on AFMD. Stifel Nicolaus reduced their price target on Affimed from $2.00 to $1.00 […]
Affimed (NASDAQ:AFMD – Get Rating) is scheduled to post its quarterly earnings results before the market opens on Tuesday, May 23rd. Analysts expect Affimed to post earnings of ($0.22) per share for the quarter. Affimed (NASDAQ:AFMD – Get Rating) last posted its quarterly earnings results on Thursday, March 23rd. The biopharmaceutical company reported ($0.22) earnings […]
HEIDELBERG, Germany, May 16, 2023 -- Affimed N.V. , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will... | May 16, 2023